<DOC>
	<DOCNO>NCT00072618</DOCNO>
	<brief_summary>The purpose study determine combination Taxotere exisulind effective safe treatment patient advance NSCLC fail prior platinum-containing regimen .</brief_summary>
	<brief_title>Phase II Study Taxotere Combination With Exisulind Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>Histologically document advanced cancer advance platinumrefractory nonsmall cell lung cancer . Platinum refractory define progressive disease platinum regimen within 6 month follow treatment . Negative serum pregnancy test , fertile female . Have take sulindac ( Clinoril® ) regular basis indication one week prior enrollment willing remain sulindac duration study . &gt; 18 year legal age . Male patient , nonpregnant nonlactating female patient either use adequate birth control ( oral contraceptive Provera ) , surgically sterile postmenopausal . Willingness remain chronic NSAIDs ( exception ibuprofen , naproxen , aspirin ) duration study . Low dose aspirin cardiovascular prevention acceptable . No treatment chemotherapy radiotherapy within 2 week prior enter study . Any condition medication may interfere conduct study . Known hypersensitivity sulindac ( Clinoril® ) taxanes . Use investigational medication device within one month initiate study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>